Pacira BioSciences Inc. (NASDAQ:PCRX) saw an upside of 3.26% to close Friday at $37.72 after adding $1.19 on the day. The 5-day average trading volume is 392,400 shares of the company’s common stock. It has gained $37.98 in the past week and touched a new high 2 times within the past 5 days. An average of 602,130 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 623,538.
PCRX’s 1-month performance is -0.29% or $0.33 on its low of $34.08 reached on 08/02/23. The company’s shares have touched a 52-week low of $34.08 and high of $58.74, with the stock’s rally to the 52-week high happening on 05/01/23. YTD, PCRX has lost -2.31% or -$0.89 and has reached a new high 11 times. However, the current price is down -35.78% from the 52-week high price.
Insider Transactions
PCRX stock investors last saw insider trading activity on Aug 02.WINSTON ROY (Chief Medical Officer) most recently sold 509 shares at $34.88 per share on Aug 02. This transaction cost the insider $17,751. Senior Vice President, Finance, Riker Lauren Bullaro, sold 643 shares at a price of $38.91 on Jul 05. Then, on Jun 14, Senior Vice President, Finance Riker Lauren Bullaro sold 6,366 shares at a price of $38.42 per share. This transaction amounted to $244,606.
Valuation Metrics
PCRX stock has a beta of 0.68. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.53 while the price-to-book (PB) in the most recent quarter is 2.15, with the price to cash flow ratio at 13.38.
Pacira BioSciences Inc.’s quick ratio for the period ended June 29 was 3.10, with the current ratio over the same period at 3.90. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.66, while the total debt to equity was 0.68. In terms of profitability, the gross margin trailing 12 months is 68.60%. The trailing 12-month EBITDA margin is 24.36% while for the period ending June 29, Pacira BioSciences Inc.’s operating margin was 4.70%. The firm’s gross profit as reported stood at $467.53 million against revenue of $666.82 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 22.83% to $25.76 million, while revenue of -$19.54 million was 175.85% off the previous quarter. Analysts expected PCRX to announce $0.76 per share in earnings in its latest quarter, but it posted $0.78, representing a 2.60% surprise. EBITDA for the quarter stood at more than $59.65 million. PCRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 734.41 million, with total debt at $620.71 million. Shareholders hold equity totaling $46.42 million.
Let’s look briefly at Pacira BioSciences Inc. (PCRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 53.31% to suggest the stock is trending Neutral, with historical volatility in this time period at 24.73%.
The stock’s 5-day moving average is $37.05, reflecting a +0.40% or $0.15 change from its current price. PCRX is currently trading +1.75% above its 20-day SMA, -5.86% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +0.48% and SMA200 by-27.13%.
Stochastic %K and %D was 49.45% and 48.25% and the average true range (ATR) pointed at 1.38. The RSI (14) points at 51.09%, while the 14-day stochastic is at 59.87% with the period’s ATR at 1.39. The stock’s 9-day MACD Oscillator is pointing at -0.35 and -0.48 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Pacira BioSciences Inc. (NASDAQ: PCRX), TD Cowen upgraded it to an Outperform rating. They previously had a Market perform rating on the stock. Analysts offering their rating for PCRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate PCRX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 8 have offered a “buy” rating.
What is PCRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $46.00 and a high of $70.00, with their median price target at $55.00. Looking at these predictions, the average price target given by analysts is for Pacira BioSciences Inc. (PCRX) stock is $55.89.
